Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

ECMO use in cystic fibrosis with severe respiratory failure showed limited survival, highlighting the need for cautious ...

Cystic fibrosis (CF) is a rare autosomal recessive disorder that affects numerous systems of the body. It is a complicated ...

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

The prevalence of food allergy is significantly lower in children with cystic fibrosis than in those without the condition in ...

North Carolina man created a foundation to help other patients navigate expenses of an unexpectedly longer life ...

At 7 years old, Morgan Barrett was diagnosed with cystic fibrosis. Prior to her diagnosis, she struggled to gain weight ...

A small group of Australians with the rarest kinds of cystic fibrosis – fewer than 200 people – will, for the first time, ...

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years ...

Affordable access to life-changing treatment for cystic fibrosis will be expanded to more Australians with a change to the ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® ...

Most children with CF treated at a San Francisco CF clinic did not receive CF liver disease screening in accordance with current guidelines.